发布求助
文献互助 智能选刊 最新文献

Cancer chemotherapy reports最新文献

筛选
英文 中文
Inhibition of deamination of 14C-cytosine arabinoside (NSC-63878): a useful biologic assay for tetrahydrouridine (NSC-112907). 抑制14c -胞嘧啶arabinoside脱胺:一个有用的四氢吡啶(NSC-112907)的生物测定。
Cancer chemotherapy reports Pub Date : 1975-07-01
R L Furner, L B Mellett
{"title":"Inhibition of deamination of 14C-cytosine arabinoside (NSC-63878): a useful biologic assay for tetrahydrouridine (NSC-112907).","authors":"R L Furner,&nbsp;L B Mellett","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inhibition of the deamination of 14C-cytosine arabinoside by two lots of tetrahydrouridine was studied in monkey serum. The average inhibition of deaminase activity was 78% for tetrahydrouridine lot AJ39 (1.0 muM) when the concentration of cytosine arabinoside ranged from 44.2 to 170.7 muM; under the same conditions tetrahydrouridine lot AJ22 inhibited deamination by an average of 68%. Apparent Ki values were 0.26 muM for AJ39 and 0.43 muM for AJ22. The assay may be used to check the relative biologic activity of various lots of tetrahydrouridine.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"717-20"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11996960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytokinetic aspects of clinical drug resistance. 临床耐药的细胞动力学方面。
Cancer chemotherapy reports Pub Date : 1975-07-01
R A Bender, R L Dedrick
{"title":"Cytokinetic aspects of clinical drug resistance.","authors":"R A Bender,&nbsp;R L Dedrick","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"805-9"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemical assay for the antitumor agent inosine dialdehyde (NSC-118994) in biologic fluids. 生物体液中抗肿瘤剂肌苷双醛(NSC-118994)的化学分析。
Cancer chemotherapy reports Pub Date : 1975-07-01
R L Cysyk
{"title":"Chemical assay for the antitumor agent inosine dialdehyde (NSC-118994) in biologic fluids.","authors":"R L Cysyk","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inosine dialdehyde, an antitumor agent highly active against several murine tumors, ispresently undergoing clinical trial for potential activity in man. To aid in the clinical evaluation of this drug, a chemical assay has been developed for the determination of concentrations of inosine dialdehyde in biologic fluids. The method involves reaction of inosine dialdehyde with phenylhydrazine in an acetic acid medium, followed by extraction of the product into ether and determining its absorbance at 378 nm. The reaction is specific for free inosine dialdehyde and will quantitate amounts as low as 1.0 mug.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"685-7"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of the effects of antitumor drugs on cell cycle kinetics. 抗肿瘤药物对细胞周期动力学的影响分析。
Cancer chemotherapy reports Pub Date : 1975-07-01
K B Woo, L B Brenkus, K M Wiig
{"title":"Analysis of the effects of antitumor drugs on cell cycle kinetics.","authors":"K B Woo,&nbsp;L B Brenkus,&nbsp;K M Wiig","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A cell cycle stage-specific multicompartmental model has been developed and used to investigate the effects of antitumor drugs on the proliferation of tumors. The drug effects simultaneously considered are (a) non-cycle-specific killing and cycle stage-specific killing of cells, (b) progression delay of cells through the cell cycle phases which may bring about an accumulation of cells in various phases of the cell cycle, and (c) prolongation of cell cycle times. These effects are analyzed in terms of possible variations in the behavior of cell kinetic parameters (namely, cell cycle times, cell loss rate, and growth fraction) and are implemented in the model specifying proper functional forms for the parameters. The time-course of drug distribution in a tumor-host system is also described by a two-compartment model and the factors affecting drug action are quantitatively formulated as a function of drug concentration. Simulation is carried out to examine the effects of BCNU, cytosine arabinoside, and methotrexate on the cell cycle and proliferation kinetics of L1210 leukemia, and the results of the simulation compare favorably with available experimental data. Also discussed are the sensitivity of drug effects to variation in dosage schedule and the different nodes of drug actions exerted on each cell cycle phase.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"847-60"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12413791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats. 柔红霉素(NSC-82151)、阿霉素(NSC-123127)及其衍生物在大鼠体内的毒理学筛选。
Cancer chemotherapy reports Pub Date : 1975-07-01
G Zbinden, E Brändle
{"title":"Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats.","authors":"G Zbinden,&nbsp;E Brändle","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The cardiotoxicity of seven anthracycline antibiotics was evaluated in small groups of rats treated with repeated intraperitoneal injections. The electrocardiogram showed a widening of the QRS complex often with the appearance of a distinct S-wave trough and occasionally with an increase or flattening of the T wave. Ventricular extrasystoles, intraventricular block, bradycardia, and heart failure developed either during treatment or after discontinuation of therapy. Based on the cumulative dose required to induce significant electrocardiographic changes, the compounds were ranked in the following order of decreasing cardiotoxicity: adriamycin, daunorubicin, NSC-149584, rubidazone, NSC-143496, daunomycin-semicarbazone, and NSC-118714. For three of these compounds used in humans (adriamycin, daunorubicin, and rubidazone) the rat screening results are in good agreement with the clinically observed cardiotoxicity.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"707-15"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary. The role of structure-activity studies in the design of antitumor agents. 评论。结构-活性研究在抗肿瘤药物设计中的作用。
Cancer chemotherapy reports Pub Date : 1975-07-01
B F Cain
{"title":"Commentary. The role of structure-activity studies in the design of antitumor agents.","authors":"B F Cain","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"679-83"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors. 鬼臼毒素新衍生物4′-去甲基幻鬼臼毒素9-(4,6-o-乙基- β -d -葡萄糖苷)的临床研究(NSC-141540;VP-16-213)，实体瘤。
Cancer chemotherapy reports Pub Date : 1975-07-01
W Felix, H J Senn
{"title":"Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.","authors":"W Felix,&nbsp;H J Senn","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The new semisynthetic epipodophyllotoxin, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540), was tested for antitumor activity against solid tumors and for clinical toxicity in 30 patients. The first two courses were given intravenously (60 mg/m2/day times 5, every 21 days), and subsequent courses were given orally (60-120 mg/m2/day times 5, every 21 days). The drug was subjectively well tolerated but induced considerable leukothrombocytopenia and alopecia. It demonstrated significant activity in oat cell carcinoma of the lung (eight responses out of 11 patients) and ovarian cancer (-our responses out of six patients). NSC-141540 has valuable cytostatic activity against these two tumors and warrants further clinical trials, especially in combination chemotherapy.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"737-42"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12280178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential biologic markers in Burkitt's lymphoma. 伯基特淋巴瘤的潜在生物学标志物。
Cancer chemotherapy reports Pub Date : 1975-07-01
T P Waalkes, C W Gehrke, W A Bleyer, R W Zumwalt, C L Olweny, K C Kuo, D B Lakings, S A Jacobs
{"title":"Potential biologic markers in Burkitt's lymphoma.","authors":"T P Waalkes,&nbsp;C W Gehrke,&nbsp;W A Bleyer,&nbsp;R W Zumwalt,&nbsp;C L Olweny,&nbsp;K C Kuo,&nbsp;D B Lakings,&nbsp;S A Jacobs","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Specific biochemical molecules used as potential biologic markers, including modified nucleosides, polyamines, and pyrimidine catabolic end-products, were quantitatively measured in the urine of seven patients with Burkitt's lymphoma before, during, and after one or more courses of therapy. The results of this preliminary study demonstrated that patients with this disease frequently excrete significantly increased amounts oof modified nuceleosides (considered to be derived primarily from transfer ribonucleic acid), polyamines, and beta-aminoisobutyric acid during the course of their disease. With successful treatment and rapid destruction of tumor cells, a concomitant rise in these molecules occurs. Elevations were observed prior to chemotherapy and changes in levels associated with treatment or tumor progression appeared to correlate with disease status and to aid in assessing antitumor response. Periodic follow-up analysis of these molecules may be helfful in appraising relapse or recurrence of the malignancy prior to overt evidence of tumor by existing clincial means.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"721-7"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac uptake of adriamycin (NSC-124127) not affected by strophanthin G (NSC-25485). 阿霉素(NSC-124127)的心脏摄取不受strophthin G (NSC-25485)的影响。
Cancer chemotherapy reports Pub Date : 1975-07-01
N R Bachur, W Reiter, E Arena
{"title":"Cardiac uptake of adriamycin (NSC-124127) not affected by strophanthin G (NSC-25485).","authors":"N R Bachur,&nbsp;W Reiter,&nbsp;E Arena","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"765-5"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of selected experimental brain tumor models used in chemotherapy experiments. 用于化疗实验的实验性脑肿瘤模型综述。
Cancer chemotherapy reports Pub Date : 1975-07-01
P C Merker, I Wodinsky, R I Geran
{"title":"Review of selected experimental brain tumor models used in chemotherapy experiments.","authors":"P C Merker,&nbsp;I Wodinsky,&nbsp;R I Geran","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"729-36"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信